ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1451

Predictors and Patterns of Fragility Fracture in an Observational Cohort of Patients with Psoriatic Arthritis
Abstract Number: 1452

Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Abstract Number: 1453

Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
Abstract Number: 1454

Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Abstract Number: 1455

Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Abstract Number: 1456

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Abstract Number: 1457

Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Abstract Number: 1458

Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients
Abstract Number: 1459

Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
Abstract Number: 1460

Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Abstract Number: 1461

Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center
Abstract Number: 1462

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Abstract Number: 1463

Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
Abstract Number: 1464

Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Abstract Number: 1465

The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].